Zimbabwe has turned down a major American healthcare agreement worth $367m (£272m) spanning five years because of Washington's demand for confidential biological samples.
This rejection came to light following a internal memorandum dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government representative later explained that the US was seeking genetic material for scientific study and profit but was unwilling to guarantee the benefits from future medical innovations.
"We will now turn to the challenging and unfortunate task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued negotiations to find a deal agreeable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Context
This development comes after a comparable case in Kenya, where a high court suspended a related deal with the US after concerns were filed about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost transparency and accountability.
Based on statements, 16 African countries have so far agreed to similar health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"In essence, our country would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be accessible to our citizens should a future disease outbreak arise."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were upending frameworks already established via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to manage potential global health emergencies.
"This system is intended to ensure that when a country contributes its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage continued dialogue with our US partners on how subsequent collaboration could be designed in a way that honours the independence and interests of each country."
Medical Community Reaction
Medical experts stated it acknowledged the government's concerns, but suggested that negotiations need to persist since a large portion of the country's HIV programmes relied on international support.
"If technical issues arise, including those involving data governance or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
This impasse underscores the complex challenges between accepting vital international aid and safeguarding national sovereignty in an ever more data-driven world.